Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Integrated Animals Resource Report Resource Website |
Integrated Animals (RRID:SCR_001421) | biomaterial supply resource, material resource, organism supplier | Integrated Animals is a virtual database currently indexing available animal strains and mutants from: AGSC (Ambystoma), BCBC (mice), BDSC (flies), CWRU Cystic Fibrosis Mouse Models (mice), DGGR (flies), FlyBase (flies), IMSR (mice), MGI (mice), MMRRC (mice), NSRRC (pig), NXR (Xenopus), RGD (rats), Sperm Stem Cell Libraries for Biological Research (rats), Tetrahymena Stock Center (Tetrahymena), WormBase (worms), XGSC (Xiphophorus), ZFIN (zebrafish), and ZIRC (zebrafish). | non human animal, mutant, database, integrated, nif, FASEB list |
uses: Mouse Genome Informatics (MGI) uses: Beta Cell Biology Consortium uses: Zebrafish Information Network (ZFIN) uses: International Mouse Strain Resource uses: Bloomington Drosophila Stock Center uses: Rat Genome Database (RGD) uses: Zebrafish International Resource Center uses: Ambystoma Genetic Stock Center uses: Kyoto Stock Center uses: FlyBase uses: Mutant Mouse Resource and Research Center uses: National Swine Resource and Research Center uses: National Xenopus Resource uses: CWRU In Vivo Animal Facilities uses: Sperm Stem Cell Libraries for Biological Research uses: Tetrahymena Stock Center uses: WormBase uses: Xiphophorus Genetic Stock Center is used by: NIF Data Federation is used by: NIDDK Information Network (dkNET) has parent organization: Integrated |
Free, Freely Available | nif-0000-08137 | https://legacy.neuinfo.org/mynif/search.php?q=*&t=indexable&nif=nlx_154697-1 http://neuinfo.org/nif/nifgwt.html?query=nif-0000-08137, https://www.neuinfo.org/mynif/search.php?q=*&t=indexable&nif=nif-0000-08137-1 | SCR_001421 | NIF Animals, NIF Integrated Animals, Integrated Animal | 2026-08-03 09:31:19 | 0 | |||||||
|
Immune Tolerance Network (ITN) Resource Report Resource Website 10+ mentions |
Immune Tolerance Network (ITN) (RRID:SCR_001535) | ITN | portal, funding resource, topical portal, clinical trial, data or information resource | International clinical research consortium dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. They aim to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. In particular, they aim to: * Establish new tolerance therapeutics * Develop a better understanding of the mechanisms of immune function and disease pathogenesis * Identify new biomarkers of tolerance and disease Their goals are to identify and develop treatment game changers for tolerance modulating therapies for the treatment of immune mediated diseases and disabling conditions, and to conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders. In the Immune Tolerance Network's (ITN) unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. They develop and fund clinical trials and mechanistic studies in partnership. Their development model is a unique, interactive process. It capitalizes on their wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions worldwide. This model gives investigators special insight into developing high quality research studies. The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington. | immune tolerance, prevent, cure, disease, multiple sclerosis, therapy, biomarker, transplant |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources is related to: Immune Tolerance Network TrialShare has parent organization: Benaroya Research Institute |
Type 1 diabetes, Diabetes, Allergy, Asthma, Autoimmune disease, Transplantation, Immunological disorder | NIAID N01AI15416 | nlx_152838 | SCR_001535 | 2026-08-03 09:31:25 | 14 | |||||||
|
HALT-C Trial Resource Report Resource Website |
HALT-C Trial (RRID:SCR_001534) | HALT-C Trial, HALT-C | resource, clinical trial, data or information resource, bibliography | Multi-center, randomized controlled study designed to determine if continuing interferon long term over several years will suppress the Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation. Patient enrollment began in 2000 and was completed in 2003 at 10 clinical centers, which were supported by a data coordinating center, virological testing center, and central sample repository. Patients with chronic hepatitis C and advanced fibrosis or cirrhosis on liver biopsy who failed to respond to a previous course of interferon alfa were enrolled in this study. Patients were initially treated with a 24-week course of peginterferon alfa-2a and ribavirin. Patients who remained hepatitis C virus RNA positive were then randomized to receive maintenance, low-dose peginterferon or to be followed on no treatment. Liver biopsies were done before enrollment and after 2 and 4 years of treatment or follow-up. The endpoints were development of cirrhosis, hepatic decompensation, hepatocellular carcinoma, death, or liver transplantation. 1050 patients were randomized and followed through the 4 year randomized phase of the trial and as long as 4 years off treatment. Serum samples collected at multiple time points, DNA and liver tissue are available for scientific investigation. | interferon, progression, cirrhosis, prevention, liver cancer, liver transplantation, liver, pegylated interferon, clinical, outcome, adult human, dna, liver tissue, serum, blood, b lymphoblastoid cell-line, epstein-barr virus infection in peripheral blood mononuclear cell, peripheral blood mononuclear cell, biomaterial supply resource, formalin fixed, histology, frozen, stained liver slide, unstained liver slide, advanced fibrosis, liver biopsy, peginterferon alfa-2a, ribavirin |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Central Repository is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) |
Hepatitis C virus, Chronic hepatitis C | NIDDK | Free, Freely available | nlx_152835 | http://archives.niddk.nih.gov/haltctrial/displaypage.aspx?pagename=haltctrial/index.htm | http://www.haltctrial.org/ | SCR_001534 | Hepatitis C Antiviral Long-term Treatment against Cirrhosis, Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial, Hepatitis C Antiviral Long-term Treatment against Cirrhosis Trial | 2026-08-03 09:31:21 | 0 | |||
|
Clinical Islet Transplantation Consortium (CITC) Resource Report Resource Website 1+ mentions |
Clinical Islet Transplantation Consortium (CITC) (RRID:SCR_014385) | CITC, CIT | access service resource, service resource | Network of clinical centers and a data coordinating center established to conduct studies of islet transplantation in patients with type 1 diabetes. | type 1 diabetes, consortium, network, islet transplantation, clinical |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources is listed by: Diabetes Research Centers |
Type 1 diabetes, Diabetes | NIDDK U01 DK070431; NIAID |
SCR_014385 | Clinical Islet Transplantation Consortium | 2026-08-03 09:35:42 | 1 | |||||||
|
Stanford Diabetes Research Center Resource Report Resource Website 1+ mentions |
Stanford Diabetes Research Center (RRID:SCR_015856) | access service resource, service resource | University-affiliated center that promotes research in diabetes and related metabolic and endocrine disorders at Stanford University. | stanford, diabetes, research center, niddk, service resource |
is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers has organization facet: Stanford Diabetes Research Center Diabetes Immune Monitoring Core has organization facet: Stanford Diabetes Research Center Stanford Islet Research Core has organization facet: Stanford Diabetes Research Center Diabetes Clinical and Translational Core has organization facet: Stanford Diabetes Research Center Diabetes Genomics Analysis Core is organization facet of: Diabetes Research Centers |
NIDDK P30 DK116074 | Available to the scientific community | SCR_015856 | 2026-08-03 09:36:27 | 1 | |||||||||
|
Digestive Diseases Statistics for the United States Resource Report Resource Website |
Digestive Diseases Statistics for the United States (RRID:SCR_006703) | Digestive Diseases Statistics for the United States | resource, data or information resource | A collection of statistics about specific digestive diseases, including prevalence, mortality, care delivery and cost. | epidemiology, prevalence, mortality, care delivery, cost, statistics, ambulatory care visit, hospitalization, inpatient procedure, surgical procedure |
is related to: NIDDK Information Network (dkNET) has parent organization: National Digestive Diseases Information Clearinghouse |
Digestive disease, Viral Hepatitis, Hepatitis B, Hepatitis A, Hepatitis C, Peptic Ulcer Disease, Pancreatitis, Liver disease, Irritable Bowel Syndrome, Ulcerative colitis, Hemorrhoid, Gastrointestinal infection, Gastroesophageal reflux disease, Gallstone, Diverticular disease, Chronic constipation, Abdominal wall hernia | NIDDK | nlx_152697 | SCR_006703 | Digestive Diseases in the United States: Epidemiology and Impact | 2026-08-03 09:33:08 | 0 | ||||||
|
Program to Reduce Incontinence by Diet and Exercise Resource Report Resource Website 5000+ mentions |
Program to Reduce Incontinence by Diet and Exercise (RRID:SCR_009018) | PRIDE | resource, clinical trial | Randomized controlled trial being conducted at two clinical centers in the United States to learn more about the effects of weight loss on urinary incontinence. About 330 overweight women aged 30 or older will participate and will be followed for 18 months. Efficacy of weight reduction as a treatment for urinary incontinence will be examined at 6 months following the intensive weight control program, and the sustained impact of the intervention will be examined at 18 months. To increase the maintenance of weight reduction and facilitate evaluation of the enduring impact of weight loss on urinary incontinence, they propose to study a motivation-based weight maintenance program. At the end of the intensive weight control program, women randomized to the weight loss program will be randomized to either a 12-month skill-based maintenance intervention or to a motivation-based maintenance intervention. The maintenance interventions maximize the potential for sustained weight loss and will allow them to determine if long-term weight reduction will produce continued improvement in urinary incontinence. | female, adult human, weight reduction, intervention, behavior, diet, exercise, motivation, weight maintenance |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of California at San Francisco; California; USA |
Urinary incontinence, Obesity, Weight loss, Overweight, Aging | NIDDK UO1 DK67860 | PMID:20664387 PMID:20680012 PMID:19179316 PMID:20643425 |
nlx_152847 | SCR_009018 | PRIDE (Program to Reduce Incontinence by Diet and Exercise) | 2026-08-03 09:34:18 | 6544 | |||||
|
ACCORD Resource Report Resource Website 100+ mentions |
ACCORD (RRID:SCR_009015) | ACCORD | resource, clinical trial | Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study. | middle adult human, late adult human, glycemic control, lowering lipid drug, blood pressure, lipid, clinical |
is related to: NIDDK Information Network (dkNET) has parent organization: National Heart Lung and Blood Institute |
Cardiovascular disease, Stroke, Type 2 diabetes, Diabetes, Aging | NHLBI ; NIDDK ; NEI ; CDC ; NIA |
PMID:23490598 PMID:23253271 PMID:23238658 PMID:22723583 PMID:22646230 |
nlx_152746 | SCR_009015 | Action to Control Cardiovascular Disease Risk in Diabetes | 2026-08-03 09:34:02 | 173 | |||||
|
Irritable Bowel Syndrome Outcome Study Resource Report Resource Website |
Irritable Bowel Syndrome Outcome Study (RRID:SCR_001504) | IBSOS | resource, clinical trial | Multi-center placebo-controlled randomized clinical trial to assess the short-term and long-term efficacy of cognitive behavior therapy (CBT) for irritable bowel syndrome (IBS) using two treatment delivery systems: self administered CBT and therapist administered CBT. Long term project goals are to develop an effective self-administered behavioral treatment program that can enhance the quality of patient care, improve clinical outcomes, and decrease the economic and personal costs of one of the most prevalent and intractable gastrointestinal disorders. | gastrointestinal disorder, cognitive behavior therapy, self-management, self-administered |
is listed by: NIDDK Information Network (dkNET) has parent organization: University at Buffalo; New York; USA |
Irritable bowel syndrome | NIDDK 5U01DK077738-07 | PMID:22846389 | Free | nlx_152839 | SCR_001504 | 2026-08-03 09:31:22 | 0 | |||||
|
Folic Acid for Vascular Outcome Reduction in Transplantation Resource Report Resource Website 1+ mentions |
Folic Acid for Vascular Outcome Reduction in Transplantation (RRID:SCR_001505) | FAVORIT | resource, clinical trial | Multi-center, randomized, double blind controlled clinical trial to determine whether treatment with a standard multivitamin augmented with high doses of folic acid, vitamin B6 and vitamin B12 reduces the rate of cardiovascular disease outcomes in renal transplant recipients relative to participants receiving a similar multivitamin that contains no folic acid. This study hopes to show that by reducing the level of homocysteine in the body, the risk of heart disease is also reduced among kidney transplant patients. | multivitamin, folic acid, vitamin b6, vitamin b12, outcome, homocysteine, adult human, middle adult human, late adult human, vitamin, bibliography |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Cardiovascular disease, Kidney transplant recipient | NIDDK U01DK061700 | PMID:16923411 | Free, Freely available | nlx_152827 | http://www.cscc.unc.edu/favorit/ | http://www.cscc.unc.edu/favorit/favdescrip.htm | SCR_001505 | Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) | 2026-08-03 09:31:20 | 1 | ||
|
Family Investigation of Nephropathy of Diabetes Resource Report Resource Website |
Family Investigation of Nephropathy of Diabetes (RRID:SCR_001525) | FIND, F.I.N.D. | resource, clinical trial | Multicenter observational study designed to identify genetic determinants of diabetic nephropathy. It is conducted in eleven U.S. clinical centers and a coordinating center, and with four ethnic groups (European Americans, African Americans, Mexican Americans, and American Indians). Two strategies are used to localize susceptibility genes: a family-based linkage study and a case-control study using mapping by admixture linkage disequilibrium (MALD). In the family-based study, probands with diabetic nephropathy are recruited with their parents and selected siblings. Linkage analyses will be conducted to identify chromosomal regions containing genes that influence the development of diabetic nephropathy or related quantitative traits such as serum creatinine concentration, urinary albumin excretion, and plasma glucose concentrations. Regions showing evidence of linkage will be examined further with both genetic linkage and association studies to identify genes that influence diabetic nephropathy or related traits. Two types of MALD studies are being done. One is a case-control study of unrelated individuals of Mexican American heritage in which both cases and controls have diabetes, but only the case has nephropathy. The other is a case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring are genotyped when available to provide haplotype data. The specific goals of this program: * Delineate genomic regions associated with the development and progression of renal disease(s) * Evaluate whether there is a genetic link between diabetic nephropathy and diabetic retinopathy * Improve outcomes * Provide protection for people at risk and slow the progression of renal disease * Help establish a resource for genetic studies of kidney disease and diabetic complications by creating a repository of genetic samples and a database * Encourage studies of the genetics of progressive renal disease | genetic susceptibility, genetic pathway, renal, kidney, outcome, gene, genetics, european-american, african-american, mexican-american, american-indian, linkage association study, admixture linkage disequilibrium, mapping by admixture linkage disequilibrium, serum creatinine, urinary protein excretion, plasma glucose level, blood pressure, blood lipid level, trait, linkage, adult human, male, female, clinical |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
NIDDK 5R01DK053591 | PMID:15642484 | Free, Freely available | nlx_152825 | https://www.niddkrepository.org/studies/find/ | SCR_001525 | Family Investigation of Nephropathy and Diabetes (F.I.N.D.), Family Investigation of Nephropathy & Diabetes | 2026-08-03 09:31:25 | 0 | ||||
|
HALT PKD Resource Report Resource Website 1+ mentions |
HALT PKD (RRID:SCR_001529) | HALT PKD, HALT-PKD | resource, clinical trial | Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease. | treatment, renal function, lisinopril, placebo, telmisartan, male, female, adolescent, adult human |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Washington University School of Medicine in St. Louis; Missouri; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK062408 | Free, Freely available | nlx_152832 | https://www.niddkrepository.org/studies/halt-pkd/ | http://www.pkd.wustl.edu/pkdtn/ | SCR_001529 | Polycystic Kidney Disease-Treatment Network | 2026-08-03 09:31:22 | 1 | |||
|
Clinical Islet Transplantation Study Resource Report Resource Website 1+ mentions |
Clinical Islet Transplantation Study (RRID:SCR_001515) | CIT Study | resource, clinical trial | Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation. | islet transplantation, islet, insulin, beta cell, pancreas, autoimmune, clinical | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | NIDDK U01DK070431 | Free, Freely available | nlx_152840 | SCR_001515 | Clinical Islet Transplantation Trial, Islet Transplantation Trials for Type 1 Diabetes | 2026-08-03 09:31:25 | 4 | |||||
|
RiVuR Resource Report Resource Website 1+ mentions |
RiVuR (RRID:SCR_001539) | RIVUR | resource, clinical trial | Multicenter, randomized, double-blind, placebo-controlled trial is designed to determine whether daily antimicrobial prophylaxis is superior to placebo in preventing recurrence of urinary tract infection (UTI) in children with vesicoureteral reflux (VUR). The basic eligibility criteria are: (1) age at randomization of at least 2 months, but less than 6 years, (2) a diagnosed first febrile or symptomatic UTI within 42 days prior to randomization that was appropriately treated, and (3) presence of Grade I-IV VUR based on voiding cystourethrogram (VCUG). Patients will be randomly assigned to treatment for 2 years with daily antimicrobial prophylaxis (trimethoprim-sulfamethoxazole) or placebo. The study is designed to recruit 600 children (approximately 300 in each treatment group) over an 18-24 month period. The primary endpoint is recurrence of UTI. In addition, patients will be evaluated for secondary endpoints related to renal scarring and antimicrobial resistance. Scarring will be determined based on renal scintigraphy by 99mTc dimercaptosuccinic (DMSA) scan. Quality of life, compliance, safety parameters, utilization of health resources, and change in VUR will be assessed periodically throughout the study. | child, antimicrobial prophylaxis, placebo, antibiotic, renal scarring, pediatric, trimethoprim-sulfamethoxazole, intervention, kidney, antibiotic resistance, young human, infant, bibliography, clinical, trimethoprim, sulfamethoxazole |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of North Carolina at Chapel Hill; North Carolina; USA |
Vesico-ureteral reflux, Urinary tract infection | NIDDK | PMID:19570724 PMID:19018048 PMID:18076937 PMID:19018047 PMID:19086141 |
Free, Freely available | nlx_152848 | http://www.cscc.unc.edu/rivur/ | SCR_001539 | Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR), Randomized Intervention for Children with Vesicoureteral Reflux, Randomized Intervention for Vesicoureteral Reflux | 2026-08-03 09:31:21 | 1 | |||
|
Type 1 Diabetes Preclinical Testing Program Resource Report Resource Website |
Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) | T1D-PTP, NIDDKT1D-PTP | resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. | testing, therapeutic, clinical, drug, preclinical, therapy, drug development, high-throughput screening, animal model, formulation, pharmacology, toxicology |
is related to: Type 1 Diabetes - Rapid Access to Intervention Development is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152741 | SCR_006861 | Type 1 Diabetes Preclinical Testing Program (T1D-PtP), NIDDKType 1 Diabetes Preclinical Testing Program | 2026-08-03 09:33:16 | 0 | |||||
|
Functional Dyspepsia Treatment Trial Resource Report Resource Website |
Functional Dyspepsia Treatment Trial (RRID:SCR_006691) | FDTT | resource, clinical trial | Multi-center, randomized, placebo-controlled trial evaluating the tricyclic antidepressant, amitriptyline and the selective serotonin reuptake inhibitor (SSRI), escitalopram to placebo in patients with functional dyspepsia. The purpose of this study is to determine whether amitriptyline and escitalopram are more efficacious than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidities. | antidepressant, amitriptyline, selective serotonin reuptake inhibitor, escitalopram, placebo |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Functional dyspepsia | NIDDK | PMID:22343090 | nlx_152830 | SCR_006691 | Antidepressant Therapy for Functional Dyspepsia, Functional Dyspepsia Treatment Trial (FDTT) | 2026-08-03 09:33:07 | 0 | |||||
|
Maryland Genetics of Interstitial Cystitis Resource Report Resource Website |
Maryland Genetics of Interstitial Cystitis (RRID:SCR_006992) | MaGIC | resource, clinical trial | Clinical study that investigated several hundred families with two or more blood relatives with interstitial cystitis in order to understand the molecular genetic basis of this condition. The study sought to find changes in genes that are found far more commonly in family members who have interstitial cystitis than in those who do not have the disease. Identifying these genes should lead to a better understanding of the cause of interstitial cystitis. This is a national study which is conducted by telephone and mail, and in which participants could participate entirely from their home. | male, female, adolescent, adult human, genetics, risk factor, family history, bladder, pain, observational |
is related to: NIDDK Information Network (dkNET) has parent organization: ClinicalTrials.gov has parent organization: University of Maryland School of Medicine; Maryland; USA |
Interstitial cystitis | NIDDK | nlx_152843 | http://icresearch.umaryland.edu/magic.aspx | SCR_006992 | Maryland Genetics of Interstitial Cystitis (MaGIC) | 2026-08-03 09:33:13 | 0 | |||||
|
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis Resource Report Resource Website |
High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (RRID:SCR_006772) | HUSC | resource, clinical trial | Multi-center, placebo-controlled trial of ursodiol in primary sclerosing cholangitis (PSC). A total of 150 patients with previously untreated PSC without cirrhosis were randomly assigned to receive high doses of ursodiol (20-25 mg/kg/day) or placebo for two years. Patients underwent medical evaluation, endoscopic retrograde cholangiography, and liver biopsy before randomization and again at two-year intervals. The endpoints of therapy were progression of hepatic fibrosis, liver decompensation, liver transplantation, or death. The treatment phase of the study was stopped for futility in June 2008; however, patients continue to be followed. Ongoing mechanistic studies are underway. | treatment, placebo, ursodeoxycholic acid, intervention, randomized, adult human, male, female |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: ClinicalTrials.gov |
Primary Sclerosing Cholangitis | NIDDK | PMID:19585548 | nlx_152836 | SCR_006772 | Trial of High-dose Urso in Primary Sclerosing Cholangitis, High-dose Ursodiol Therapy of Primary Sclerosing Cholangitis (HUSC), Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis | 2026-08-03 09:33:14 | 0 | |||||
|
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit Resource Report Resource Website |
Efficacy and Mechanisms of Glutamine Dipeptide in the Surgical Intensive Care Unit (RRID:SCR_006806) | GLND | resource, clinical trial | Multi-center, double-blind, placebo-controlled, intent-to-treat Phase III trial, designed to determine the effect of parenteral glutamine (GLN) dipeptide on important clinical outcomes in patients requiring surgical intensive care unit (SICU) care and parenteral nutrition (PN) after cardiac, vascular, or intestinal surgery. Patients who required PN and SICU care will receive either standard glutamine (GLN)-free PN (STD-PN) or isocaloric, isonitrogenous alanyl-glutamine dipeptide (AG)-PN until enteral feedings are established. The study will determine whether AG-PN decreases hospital mortality, nosocomial infection and other important indices of morbidity and will obtain mechanistically relevant observational data in the subjects on whether AG-PN a) increases serial blood concentrations of glutathione (GSH), heat shock proteins (HSP)-70 and -27, and glutamine; b) decreases the serum presence of the bacterial products flagellin and lipopolysaccharide (LPS) and the adaptive immune response to these mediators; and c) improves key indices of innate and adaptive immunity. | parenteral nutrition, glutamine, glutamine dipeptide, clinical, outcome, adult human, mortality, nosocomial infection, immune cell function, hospital morbidity, morbidity, intensive care |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: Emory University; Georgia; USA |
Critical illness | NIDDK U01DK069322 | PMID:18596310 | nlx_152823 | http://www.sph.emory.edu/GLND | SCR_006806 | Phase III Study on the Efficacy of Glutamine Dipeptide-Supplemented Parenteral Nutrition in Surgical ICU Patients, Efficacy and Mechanisms of GLN Dipeptide in the SICU, Efficacy and Mechanisms of GLN Dipeptide in the SICU (GLND), GLND trial | 2026-08-03 09:33:15 | 0 | ||||
|
Frequent Hemodialysis Network Nocturnal Trial Resource Report Resource Website |
Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) | FHN Nocturnal Trial | resource, clinical trial | Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia | hemodialysis, home, adult human, kidney, kidney disease |
is listed by: ClinicalTrials.gov is related to: Frequent Hemodialysis Network Daily Trial is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
End Stage Renal Disease, Hemodialysis | NIDDK | PMID:21775973 PMID:17164834 PMID:17699439 |
nlx_152829 | SCR_007014 | Frequent Hemodialysis Network (FHN) Nocturnal Trial, Frequent Hemodialysis Network: Nocturnal Trial | 2026-08-03 09:33:16 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
